Chapter 3 - The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
Introduction
Cells in multicellular organisms are continuously exposed to DNA damage arising from a variety of endogenous and exogenous sources. These include reactive oxygen species, ultraviolet light, background radiation, and environmental mutagens. To protect their genomes from this assault, cells have evolved complex mechanisms, collectively referred to as DNA damage responses, that act to rectify damage and minimize the probability of lethal or permanent genetic damage. The cellular response to DNA damage encompasses multiple repair mechanisms and checkpoint responses that can delay cell cycle progression or modulate DNA replication. Collectively, these processes are essential to maintain genome stability.
DNA damage responses are orchestrated by multiple signal transduction processes, key among which are the ATM–Chk2 and ATR–Chk1 pathways. Activation of these pathways is crucial for the proper coordination of checkpoint and DNA repair processes; however, they can also modulate other biological outcomes such as apoptosis or cell senescence. In recent years, it has become evident that DNA damage responses are central both for the evolution and therapy of cancer. Inherited defects in DNA damage responses predispose to cancer by enhancing the accumulation of oncogenic mutations, while genome instability is also common in sporadic cancers. More recently, it has become apparent that oncogenic mutations elicit spontaneous DNA damage that can suppress the evolution of incipient cancer cells. Escape from this tumor suppressive barrier may be a major factor in selecting for additional genetic changes during tumor progression such as mutation of the p53 tumor suppressor, the most frequent alteration in human cancer.
Conversely, radiation and genotoxic chemotherapies remain a mainstay of conventional cancer treatment and are likely to remain so for the foreseeable future. Such therapies are, however, imperfect and can incur severe side effects. As a result, much current interest is focused on understanding how normal and tumor cells respond to DNA damage and determining whether DNA damage responses could be exploited or manipulated for therapeutic purposes. Two concepts in particular have attracted attention in recent years. First, inherent defects in genome stability mechanisms, such as homologous recombination, can confer tumor sensitivity to specific genotoxic agents or inhibition of complementary repair pathways. Second, evidence suggests that pharmacological suppression of DNA damage or checkpoint responses can enhance the efficacy of conventional genotoxic agents. Although promising, a full understanding of the biology and functions of the DNA damage signaling pathways will be crucial for the future success of such approaches.
Section snippets
Activation of the ATM–Chk2 and ATR–Chk1 DNA Pathways
DNA damage responses are controlled by biochemical pathways whose principal components and general organization have been conserved from yeasts to humans (Rhind and Russell, 2000). In vertebrates, the two main signaling pathways activated by DNA damage consist of the ATM–Chk2 and ATR–Chk1 protein kinases (Sancar et al., 2004). ATM and ATR are large kinases with sequence similarity to lipid kinases of the phosphatidylinositol-3-kinase (PI3K) family, but which phosphorylate only protein
Checkpoint Functions of the ATM–Chk2 and ATR–Chk1 Pathways
DNA damage or DNA synthesis inhibition in vertebrate cells evokes the activation of multiple, mechanistically distinct checkpoint responses that facilitate repair and promote cell survival (Kastan and Bartek, 2004). As shown in Fig. 2, DNA damage induces cell cycle delays at the G1/S and G2/M transitions (the G1 and G2 checkpoints), and a transient decrease in the rate of DNA synthesis (the intra-S checkpoint). Of these, the G1 checkpoint is unique in depending primarily on the function of the
The Three Rs of Damage Signaling: Resection, Recombination, and Repair
In eukaryotes DNA DSBs are repaired via two main mechanisms; nonhomologous end-joining (NHEJ) and homologous recombination repair (HRR). NHEJ occurs throughout the cell cycle; however, because HRR requires a sister chromatid to serve as a template, this mechanism is restricted to the S and G2 phases. Unlike NHEJ, HRR requires extensive DNA damage processing to generate tracts of ssDNA that, once coated with Rad51 recombinase, invade the homologous DNA duplex to initiate repair. Such
ATM–Chk2 and ATR–Chk1 Pathway Alterations in Cancer
The importance of genome stability for preventing carcinogenesis is evident both from human cancer predisposition syndromes that result from inherited loss-of-function mutations in DNA damage response genes and from the occurrence of sporadic mutations affecting such genes in cancers in otherwise genetically normal individuals (Kastan and Bartek, 2004). Examples of both have been found to affect ATM and Chk2 in human cancer, whereas ATR and Chk1 appear to be mutated only rarely. Important
Exploiting Homologous Recombinational Repair (HRR) Defects for Cancer Therapy
In recent years it has emerged that in addition to predisposing to cancer as a result of increased genomic instability, defective HRR may also render tumor cells inherently vulnerable to specific conventional anticancer agents and also to new strategies based on inhibition of complementary repair pathways. Thus, BRCA1- and BRCA2-deficient tumor cells have been found to be hypersensitive to cross-linking agents such as cisplatin in vitro (Bhattacharyya et al., 2000, Yuan et al., 1999), most
DNA Damage Signaling as a Barrier to Tumorigenesis
Predisposition syndromes demonstrate that genomic instability can promote cancer; however, in recent years an alternative paradigm has emerged in which DNA damage and the resulting downstream signaling processes act as a tumor suppression mechanism (Halazonetis et al., 2008). This concept originated with the observation that premalignant or early stage lesions in several cancer types, including bladder, breast, lung, and colon, frequently showed evidence of DNA damage as judged by the presence
Checkpoint Suppression as a Therapeutic Principle
Radiation and genotoxic chemotherapies remain the mainstays of cancer treatment. Although new, molecularly targeted, drugs like imatinib have revolutionized treatment of rare cancers such as chronic myeloid leukemia (Agrawal et al., 2010), there seems little prospect that conventional therapies will be replaced in the treatment of other, more common malignancies in the foreseeable future. Such treatments are, however, of limited efficacy and toxic not only to tumor cells but also to normal
Future Perspectives
Genomic instability has long been recognized as a cardinal feature, and arguably an important cause of, cancer, however, in recent years it has also emerged as a potential Achilles heel that offers new therapeutic opportunities. Thus far this prospect has been most evident in cancers that arise in predisposed individuals, for example in BRCA1 and BRCA2 mutation carriers, where impairment of one particular form of DNA repair specifically in tumor cells creates sensitivity to both existing and
Acknowledgments
The authors wish to thank Cancer Research-UK, the Beatson Institute for Cancer Research, and the Royal College of Radiologists (LMT) for financial support.
References (201)
Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain
J. Biol. Chem.
(2002)- et al.
Chk1 and Chk2 kinases in checkpoint control and cancer
Cancer Cell
(2003) Claspin is phosphorylated in the Chk1-binding domain by a kinase distinct from Chk1
Biochem. Biophys. Res. Commun.
(2008)The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
J. Biol. Chem.
(2000)Li-Fraumeni syndrome
Eur. J. Cancer
(1994)A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase
Curr. Biol.
(1999)- et al.
The checkpoint response to replication stress
DNA Repair (Amst)
(2009) Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele
Leuk. Res.
(2006)Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase
Mol. Cell
(2009)Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair
J. Biol. Chem.
(2008)
The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: Implications for Chk1 regulation
Cell
Repeated phosphopeptide motifs in human Claspin are phosphorylated by Chk1 and mediate Claspin function
J. Biol. Chem.
Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S-phase
J. Biol. Chem.
Regulation of early events in chromosome replication
Curr. Biol.
H2AX: The histone guardian of the genome
DNA Repair (Amst)
Human CtIP mediates cell cycle control of DNA end resection and double strand break repair
J. Biol. Chem.
The Chk2 tumor suppressor is not required for p53 responses in human cancer cells
J. Biol. Chem.
DNA repair: PARP–another guardian angel?
Curr. Biol.
Phosphorylated claspin interacts with a phosphate-binding site in the kinase domain of Chk1 during ATR-mediated activation
J. Biol. Chem.
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Cell
Tipin-replication protein A interaction mediates Chk1 phosphorylation by ATR in response to genotoxic stress
J. Biol. Chem.
Human DNA damage response and repair deficiency syndromes: Linking genomic instability and cell cycle checkpoint proficiency
DNA Repair (Amst)
Circadian proteins in the regulation of cell cycle and genotoxic stress responses
Trends Cell Biol.
Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1
J. Biol. Chem.
TopBP1 activates the ATR-ATRIP complex
Cell
Chk1 is haploinsufficient for multiple functions critical to tumor suppression
Cancer Cell
Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications
Nat. Protoc.
Cell cycle checkpoint signaling through the ATM and ATR kinases
Genes Dev.
Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex
Oncogene
Tyrosine kinase inhibitors: The first decade
Curr. Hematol. Malig. Rep.
Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation
Cancer Res.
CHK2 kinase: Cancer susceptibility and cancer therapy–two sides of the same coin?
Nat. Rev. Cancer
Keeping checkpoint kinases in line: New selective inhibitors in clinical trials
Expert Opin. Investig. Drugs
The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
Oncogene
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Nature
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Nature
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Nature
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Nature
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
Science
Cancer predisposition and hematopoietic failure in Rad50(S/S) mice
Genes Dev.
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
Genes Chromosom. Cancer
ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2
EMBO J.
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
Mol. Cancer Ther.
Replication licensing and cancer–a fatal entanglement?
Nat. Rev. Cancer
Chk1 haploinsufficiency results in anemia and defective erythropoiesis
PLoS ONE
CDC25 phosphatases in cancer cells: Key players? Good targets?
Nat. Rev. Cancer
Oncogene-induced senescence: Putting the brakes on tumor development
Cancer Res.
When mutants gain new powers: News from the mutant p53 field
Nat. Rev. Cancer
ATR disruption leads to chromosomal fragmentation and early embryonic lethality
Genes Dev.
Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance
Genes Dev.
Cited by (961)
Review: Protein O-GlcNAcylation regulates DNA damage response: A novel target for cancer therapy
2024, International Journal of Biological MacromoleculesStructural basis for intra- and intermolecular interactions on RAD9 subunit of 9-1-1 checkpoint clamp implies functional 9-1-1 regulation by RHINO
2024, Journal of Biological Chemistry